Unknown

Dataset Information

0

PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.

ABSTRACT: FDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma.

SUBMITTER: Phillips EH 

PROVIDER: S-EPMC8553182 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

PET-guided treatment for personalised therapy of Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.

Phillips Elizabeth H EH   Iype Rohan R   Wirth Andrew A  

The British journal of radiology 20210914 1127

FDG-PET scanning has a central role in lymphoma staging and response assessment. There is a growing body of evidence that PET response assessment during and after initial systemic therapy can provide useful prognostic information, and PET response has an evolving role in guiding patient care. This review provides a perspective on the role of PET response assessment for individualised management of patients with the most common aggressive lymphomas, Hodgkin lymphoma and diffuse large B-cell lymph  ...[more]

Similar Datasets

Unknown PET-guided treatment in advanced-stage Hodgkin lymphoma: yes but which one?
| S-EPMC6633886 | biostudies-literature
Unknown Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphoma.
| S-EPMC10776396 | biostudies-literature
Unknown Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification: a post-hoc analysis of the PETAL trial.
| S-EPMC9712103 | biostudies-literature
Unknown Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy.
| S-EPMC4588185 | biostudies-literature
Unknown CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma
| S-EPMC10672004 | biostudies-literature
Unknown FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
| S-EPMC5541086 | biostudies-literature
Unknown CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi.
| S-EPMC4775030 | biostudies-literature
Unknown Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy.
| S-EPMC3278154 | biostudies-literature
Unknown Enitociclib (VIP152), venetoclax and prednisone in relapsed or refractory aggressive non-Hodgkin lymphoma.
| S-EPMC12819095 | biostudies-literature
Unknown Late Adverse Events After Chimeric Antigen Receptor T-Cell Therapy for Patients With Aggressive B-Cell Non-Hodgkin Lymphoma.
| S-EPMC11862965 | biostudies-literature